Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum)…

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating to 99.2% under conventional per protocol analysis If approved, GanLum would represent first major innovation in malaria treatment since 1999, with potential to kill drug-resistant parasites and block transmissionNovel ingredient in...

Alvotech Reports Results for the First Nine Months of 2025 and Provides a…

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D...

Essity acquires Edgewell's feminine care business in North America including the…

"I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With this acquisition we are building a stronger personal care business in North America, in line with our strategy to focus on high yielding categories in attractive geographies." says Ulrika Kolsrud, President and CEO of Essity. "I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With…

Hyaluronic Acid Based Dermal Fillers Market Poised for Remarkable Growth Driven…

For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market. For a detailed analysis of Industry Trends And Growth Drivers, Explore The Full Hyaluronic Acid Based Dermal Fillers Market . Browse in-depth TOC 202 - Pages126 – Tables 37 – Figures Global Hyaluronic Acid Based Dermal Fillers Market Overview Market Driver 1. Rising Demand for Non-Surgical Aesthetic ProceduresThe increasing...

Dental Chairs Market to Reach $820.84 Million by 2027 in the short run and…

Request Sample of the Report on Dental Chairs Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/2658 Request Sample of the Report on Dental Chairs Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/2658 Market Introduction A dental chair is a specialized medical device designed to position patients ergonomically during dental procedures while ensuring optimal access for practitioners. These chairs feature adjustable headrests,...

Life Science Instrumentation Market worth $92.5 billion by 2031 with 6.5% CAGR |…

Browse in-depth TOC on "Life Science Instrumentation Market" Browse in-depth TOC on "Life Science Instrumentation Market" 300 - Tables 50 - Figures 400 - Pages By technology,the life science instrumentation market is segmented into spectroscopy, chromatography, polymerase chain reaction (quantitative PCR, digital PCR), immunoassays, lyophilization, liquid handling systems, clinical chemistry analyzers, microscopy, flow cytometry, next-generation sequencing, centrifuges,...

Fragrance Diffuser Market to Reach $55.1 billion, Globally, by 2034 at 6.7%…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A299175 Prime determinants of growth The demand for fragrance diffuser has increased as more consumers prioritize holistic well-being and seek natural ways to improve their mental and physical health. Aromatherapy, which uses essential oils to promote relaxation, reduce stress, and...

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for…

"We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission of transforming patients' lives with high quality radiopharmaceuticals drives every step of our work, and we are proud to contribute to bringing promising therapies in oncology closer to patients." said Bruno Paquin, CEO of AtomVie. "We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical…

/C O R R E C T I O N -- EirGenix, Inc./

EG1206A has completed its pharmacokinetic (PK) clinical study, and last month received positive feedback from both the U.S. FDA and the European Medicines Agency (EMA), confirming that the product qualifies for an abbreviated development pathway, allowing for the waiver of Phase III comparative efficacy trials. This agreement marks another major milestone and breakthrough in EirGenix's biosimilar development efforts. This partnership further strengthens the existing collaboration between Sandoz…

Chiesi Group Enters into an Exclusive License Agreement with Aliada…

“This agreement underscores our continued commitment to creating potential solutions that target the significant unmet needs in managing cognitive and neurological symptoms across several rare diseases,”Giacomo Chiesi, Executive Vice President,Chiesi Global Rare Diseases. “These aspects of the disease are frequently underserved, yet they can profoundly affect patients and their families. By advancing this research, we intend to go beyond symptom management and potentially address the...

Keralty and Total Care Saudi (TCS) Form Strategic Alliance to Advance Population…

The alliance seeks to shift the focus of healthcare from reactive disease management to predictive and proactive health management, guiding the evolution of TCS's successful Third-Party Administrator (TPA) model into a next-generation Population Health Services Organization (PHSO). This transformation will center on the comprehensive, integrated care of populations before they require high-cost interventions, enabling smarter use of resources and better health outcomes. The alliance seeks to...

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025…

"This past month has been transformative for the Company, marked by closing a $58.88 million private placement led by Winklevoss Capital and successfully deploying $50 million to build a digital asset treasury designed to create long-term shareholder value focused on active participation in the development of Zcash and acquiring ZEC," said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. "In our drug development business, we presented the final data from our…

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and…

- Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Society for Medical Oncology (ESMO) Annual Congress 2025 -- Next generation oncolytic virus VCN-12 preclinical data presented at the 32 ndAnnual Congress European Society of Gene & Cell Therapy (ESGCT) -- Cash and cash equivalents of $7.5 millon as of September 30, 2025; recent capital raises increase cash to $15...

Evaxion announce 2026 financial calendar

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its financial calendar for 2026 as summarized below: March 5, 2026 : Business update and full year 2025 financial results April 16, 2026 : Annual General Meeting May 7, 2026 : Business update and first quarter 2026 financial results August 20, 2026 : Business update and second quarter 2026 financial results November 19, 2026 : Business update and third...

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of…

– Alixorexton Was Generally Well Tolerated at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast onWednesday, Nov. 12at8:30 a.m. ET– DUBLIN , Nov. 12, 2025 /PRNewswire/ --Alkermes plc(Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is...

Genesis Automation Healthcare Announces Strategic Investment from Diversis…

The investment will accelerate Genesis's expansion across the United States, United Kingdom, and Ireland and advance the development of AI-powered analytics and predictive capabilities. Genesis's enhanced platform will address critical challenges in waste reduction, compliance, and clinical efficiency that healthcare organizations face worldwide. The investment will accelerate Genesis's expansion acrossthe United States,United Kingdom, andIrelandand advance the development of...

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR…

Company to hostconference call and webcasttoday, November 12, at 8:30 am EST/2:30 pm CETIMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1...

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum)…

Alvotech Reports Results for the First Nine Months of 2025 and Provides a…

Essity acquires Edgewell's feminine care business in North America including the…

Inventiva announces launch of public offering

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

IBA – TRANSPARENCY NOTIFICATION

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™…

Wandercraft and SAPA Announce Deployment Partnership in Industrial…

Head and Neck Cancer Drugs/Therapeutics Market Backed by Growing Adoption of…

Hyaluronic Acid Based Dermal Fillers Market Poised for Remarkable Growth Driven…

Dental Chairs Market to Reach $820.84 Million by 2027 in the short run and…

Life Science Instrumentation Market worth $92.5 billion by 2031 with 6.5% CAGR |…

Fragrance Diffuser Market to Reach $55.1 billion, Globally, by 2034 at 6.7%…

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for…

/C O R R E C T I O N -- EirGenix, Inc./

Chiesi Group Enters into an Exclusive License Agreement with Aliada…

Keralty and Total Care Saudi (TCS) Form Strategic Alliance to Advance Population…

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025…

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and…

Evaxion announce 2026 financial calendar

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of…

Genesis Automation Healthcare Announces Strategic Investment from Diversis…

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR…